Company intelligence / Profile preview

Mercia Pharma

Scarsdale, New York, United Statesmercia.co.uk ↗

Ownership: Private
Development stage: Other

Overview

Mercia Pharma is developing immunotherapeutic vaccines using its MERIT platform to induce antigen-specific immune tolerance or immunity. Its lead candidates are in Phase 1 trials for type 1 diabetes, with additional preclinical programs targeting Alzheimer’s disease, asthma/allergy, and influenza. The company focuses on restoring self-tolerance or protective immunity while minimizing inflammatory side effects.

Therapeutic areas: ImmunologyEndocrinologyInfectious DiseasesNeurology
Modalities: Therapeutic vaccineBiological productsRecombinant polypeptideNanoparticle (adjuvant component)Small molecule (for adjuvant/delivery system)
Industry: Biotech

Drug pipeline

5 assets

MAS-1

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Mercia Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mercia Pharma.

Explore the full profile